

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Non-Hodgkin Lymphoma: diagnosis and management

2 List of modelling questions

Review questions by scope area	Is autologous transplantation, allogeneic transplantation or no transplantation the most effective treatment for people with follicular lymphoma at various time points?
Population	Adults and young people (16 years and older) with follicular non-Hodgkin lymphoma
Interventions and comparators considered for inclusion	Autologous transplantation Allogeneic transplantation Immunochemotherapy
Perspective	NHS and personal social services (PSS)
Outcomes	Total and incremental costs Total and incremental QALYs Cost per QALY
Type of analysis	Cost-utility analysis (CUA)
Issues to note	Lack of clinical data comparing all three interventions

Review questions by scope area	Is immediate treatment or deferred chemotherapy (watch and wait) the more effective treatment for people with advanced asymptomatic follicular lymphoma?
Population	Adults and young people (16 years and older) newly diagnosed with advanced (\geq stage II) asymptomatic follicular non-Hodgkin lymphoma
Interventions and comparators considered for inclusion	Watchful waiting (with deferred chemotherapy if necessary) Rituximab induction only Rituximab induction and maintenance
Perspective	NHS and personal social services (PSS)
Outcomes	Total and incremental costs Total and incremental QALYs Cost per QALY
Type of analysis	Cost-utility analysis (CUA)
Issues to note	Lack of long term data comparing strategies